JAGRUTI C PATEL

Allopathic & Osteopathic Physicians|Plastic Surgery BEVERLY, MA NPI 1770537151

General Payments — all program years on this page

$3,358.02

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 50
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $2,242.52 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $2,242.5218

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $2,242.5218

By program year

Program yearAmountRecords
2018 $517.3416
2019 $245.419
2020 $78.352
2021 $70.412
2022 $203.993
2024 $2,242.5218

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137650270 Takeda Pharmaceuticals U.S.A., Inc. $1,017.08 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650272 Takeda Pharmaceuticals U.S.A., Inc. $225.80 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650274 Takeda Pharmaceuticals U.S.A., Inc. $139.28 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650276 Takeda Pharmaceuticals U.S.A., Inc. $197.38 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650278 Takeda Pharmaceuticals U.S.A., Inc. $122.54 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650280 Takeda Pharmaceuticals U.S.A., Inc. $33.97 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650282 Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650284 Takeda Pharmaceuticals U.S.A., Inc. $48.95 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650286 Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650288 Takeda Pharmaceuticals U.S.A., Inc. $122.54 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650290 Takeda Pharmaceuticals U.S.A., Inc. $33.97 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650292 Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650294 Takeda Pharmaceuticals U.S.A., Inc. $48.98 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650296 Takeda Pharmaceuticals U.S.A., Inc. $99.03 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650298 Takeda Pharmaceuticals U.S.A., Inc. $15.77 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650300 Takeda Pharmaceuticals U.S.A., Inc. $40.62 11/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650302 Takeda Pharmaceuticals U.S.A., Inc. $19.66 11/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137650304 Takeda Pharmaceuticals U.S.A., Inc. $18.00 11/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.